Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 20/20 | 0.60 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.52 |
| ▸ | AKT1 | P31749 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4741812 | 0.90 | PDPK1 (0.72) | PDPK1RPS6KB1AKT1 | |
| SCHEMBL4744885 | 0.84 | PDPK1 (0.61) | PDPK1DAPK3PRKD3FLT1RPS6KA3 | |
| SCHEMBL4744920 | 0.82 | PDPK1 (0.64) | PDPK1DAPK3PRKD3FLT1RPS6KA3 | |
| SCHEMBL4744942 | 0.78 | PDPK1 (0.71) | PDPK1RPS6KB1AKT1 | |
| SCHEMBL4745716 | 0.77 | PDPK1 (0.71) | PDPK1RPS6KB1AKT1 | |
| SCHEMBL4745211 | 0.76 | PDPK1 (0.71) | PDPK1RPS6KB1AKT1 | |
| SCHEMBL4742845 | 0.76 | PDPK1 (0.69) | PDPK1RPS6KB1AKT1 | |
| SCHEMBL4741501 | 0.76 | PDPK1 (0.65) | PDPK1RPS6KB1AKT1 | |
| SCHEMBL4742064 | 0.76 | PDPK1 (0.56) | PDPK1DAPK3PRKD3FLT1RPS6KA3 | |
| SCHEMBL4745647 | 0.75 | PDPK1 (1.00) | PDPK1RPS6KB1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | PDPK1 1/4885DAPK3 217/4885PRKD3 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.